Clinical Trial Update: Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating silymarin (milk thistle extract) in patients with acute lymphoblastic leukemia undergoing chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Herbert Irving Comprehensive Cancer Center | Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia | Phase 2 | Status: COMPLETED